Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein

Hematological malignancies harboring various ABL1 fusions are expected to be sensitive to tyrosine kinase inhibitors (TKIs), similar to those with BCR-ABL1. However, SEPT9-ABL1 exhibits TKI resistance both in vitro and in vivo. SEPT9-ABL1 has the same ABL1 region as seen in BCR-ABL1 but no point mut...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neoplasia
Prif Awduron: Kawai, Hidetsugu, Matsushita, Hiromichi, Suzuki, Rikio, Kitamura, Yuka, Ogawa, Yoshiaki, Kawada, Hiroshi, Ando, Kiyoshi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Neoplasia Press 2019
Pynciau:
Original article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6611969/
https://ncbi.nlm.nih.gov/pubmed/31276931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2019.06.001
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg